Evidence map›Paper›PMID 31087628›Full record

ArticleCancer medicine2019

The demographic and treatment options for patients with large cell neuroendocrine carcinoma of the lung.

Jianjun Gu, Daohui Gong, Yuxiu Wang, Beiyuan Chi, Jun Zhang, Suwei Hu, Lingfeng Min

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Neuroendocrine neoplasms of the lung: The latest updates.World journal of clinical oncology · 2025
    Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. [Advances of Treatment of Pulmonary Large Cell Neuroendocrine Carcinoma].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Risk factors associated with survival in surgically treated large cell neuroendocrine carcinoma of the lung.Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Jianjun GuClinical Medical College of Yangzhou University, Department of Respiratory Medicine, Subei People's Hospital, Yangzhou, China.ORCID 0000-0003-3521-0908
Daohui GongClinical Medical College of Yangzhou University, Department of Respiratory Medicine, Subei People's Hospital, Yangzhou, China.
Yuxiu WangDepartment of Respiratory Medicine, Subei People's Hospital, Dalian Medical University, Yangzhou, China.
Beiyuan ChiDepartment of Respiratory Medicine, Subei People's Hospital, Dalian Medical University, Yangzhou, China.
Jun ZhangClinical Medical College of Yangzhou University, Department of Respiratory Medicine, Subei People's Hospital, Yangzhou, China.
Suwei HuThe Affiliated Hospital of Yangzhou University, Yangzhou Women and Children Hospital, Yangzhou, China.
Lingfeng MinClinical Medical College of Yangzhou University, Department of Respiratory Medicine, Subei People's Hospital, Yangzhou, China.
Yangzhou University · CNDalian Medical University · CNNanjing Drum Tower Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionLung large cell neuroendocrine carcinoma (L-LCNEC) is a rare, aggressive tumor, for which the optimal treatment strategies for LCNEC have not yet been established. In order to explore how to improve the outcome of prognosis for patients with LCNEC, this study investigated the effect of different treatments based on the data obtained from the Surveillance, Epidemiology, and End Results (SEER) database.

methodsA total of 2594 LCNEC cases with conditional information were extracted from SEER database. Propensity Score Matching (PSM) method was conducted to reduce possible bias between groups. One-way ANOVA was used to test the differences of characteristics between groups. Univariate and multivariate Cox proportional hazard models were applied to identify prognostic factors.

resultsClinicopathologic characteristics including gender, age, TNM stage, T stage, N stage, and M stage were all identified as independent prognostic factors. Surgery benefited stage I, II, and III LCNEC patients' prognoses. The combination treatment that surgery combining with chemotherapy was the optimal treatment for stage I, II, and III LCENC patients. Compared with palliative treatment, stage IV patients obtained better prognoses with the treatment of radiation, chemotherapy, or chemoradiation. When comparing the effect of the three treatments (radiation, chemotherapy, and chemoradiation) in achieving better prognosis for stage IV patients, chemotherapy alone was better than the other treatments.

conclusionSurgery combining with chemotherapy was the optimal treatment for stage I, II, and III LCNEC patients; chemotherapy alone achieves more benefit than the other treatments for stage IV patients.

Indexed as

Carcinoma, NeuroendocrineFemaleHumansLung NeoplasmsMaleMiddle Agedchemotherapylarge cell neuroendocrine carcinomaprognosisradiationsurgery

Identifiers

PMID31087628
PMCPMC6558599
OpenAlexW2945887019

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.